Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia.

ABSTRACT:

Impact

Immune dysregulation is thought to contribute to chronic lymphocytic leukemia (CLL) risk, but biological mechanisms are unclear. We discovered that increased serum levels of B-cell activating factor (BAFF), an important regulator of B-cell maturation, were associated with a decreased risk of CLL, even >10 years after blood draw. Our findings suggest that BAFF could be a useful biomarker to assess risk among individuals at high risk, such as those with monoclonal b-cell lymphocytosis.

SUBMITTER: Frost E 

PROVIDER: S-EPMC11306784 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature